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S280 Poster Session Iinclude associating these findings with an accurate cost analysis of
UCBT.
Table 1. Unadjusted Associations of Transplant Characteris-
tics with Days Alive and Out of Hospital
Median Coefficient
N (IQR*) (95% CI) p-value†Age 0.16
1-19 26 43 (19-57) 0 (reference)
20-34 20 52 (23-75) 9.1 (-7.7, 25.8)
35-49 20 67 (36 – 77) 15.2 (-1.5, 31.9)
50-73 18 72 (15 -86) 18.2 (0.9, 35.4)
Institution 0.03
UW Medical Center 57 66 (28 – 79) 0
Seattle Children’s
Hospital27 40 (19 – 57) -14.9 (-28.1, -1.7)Sex 0.21
Female 42 61 (28 – 76) 0
Male 42 53 (12 – 73) -8.1 (-20.6, 4.4
Race 0.002
Caucasian 49 66 (38 – 77) 0
Non-Caucasian 35 38 (14 – 60) -19.5 (-31.6, -7.4)
Disease-Risk 0.02
Standard 74 59 (29 – 76) 0
High 10 15 (0 – 57) -22.7 (-41.6, -3.8)
CMV seropositivity 0.05
Neg 31 66 (40 – 77) 0
Pos 53 46 (14 – 73) -12.9 (-25.7, -0.1)
Comorbidity score
(in adults)0.590, 1 14 50 (34 – 64) 0
2 19 73 (38 – 79) 11.8 (-8.8, 32.4)
3 14 50 (27 – 66) -1.1 (-23.3, 21.0)
4 – 8 15 66 (15 – 83) 5.3 (-16.5, 27.0)
Conditioning
regimen0.34CY / Flu / TBI 65 59 (20 – 76) 0
Treo / Flu / TBI 19 46 (14 – 68) -7.3 (-22.4, 7.7)
TBI dose (cGy) 0.46
200 – 300 32 59 (21 – 81) 0
1320 52 54 (20 – 71) -4.9 (-17.9, 8.0)
Number of donors 0.39
1 9 38 (14 – 54) -10.9 (-31.1, 9.4)
2 71 59 (27 – 77) 0
3 4 29 (14 – 58) -14.8 (-44.2, 14.7)*IQR 5 inter-quartile range, 25th to 75th percentiles of distribution
†Test for homogeneity across factor levels207
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Introduction: Low bone mineral density (BMD) is an important
multifactorial cause of morbidity in patients with b-thalassemia.
With recent therapeutic advances such as hematopoietic stem cell
transplantation (HSCT), thalassemic patients can live longer but os-
teoporosis is now a major health concern.
Method: In this study, we evaluated the changes of bone density in
46 patients with b thalassemia major who were candidates for HSCT
before and after transplantation. The average age of patients was 13.4
years (range 3-29 years). Twenty four patients (52.2%) were male.
All patients underwent HSCT from HLA-identical related donors.
Nine patients (19.6%) co-transplanted with mesenchymal cells.
Dual-energy X-ray absorptiometry (DXA) was performed on lumbar
vertebrae and femoral neck in all patients before starting pre-
transplant regimens and repeated at one year after transplantation.
Results: Low BMD was found in 7 patients (15.2%) before trans-
plantation and in 18 patients (39.1%) one year after transplantation.BMD changes in femoral neck and lumbar area were significant at
one year after transplant (p\0.001) while no significant changes
were found in the whole femur (p 5 0.22). Female gender (p 5
0.005) and low body mass index (p 5 0.05) were correlated with
low BMD and defined as independent risk factors for low BMD at
one year after transplantation. There was no significant difference
inBMDchanges betweenpatientswith andwithout co-transplantation
of mesenchymal cells.
Conclusion:Due to decrease in BMDafterHSCT, it is suggested to
manage low BMD before transplantation. Longer follow-up will
help to better clarify the role of HSCT in BMD changes of thalasse-
mic patients; moreover, further studies are suggested to evaluate the
role of co-transplantation of HCT together with mesenchymal cells
on BMD improvement of thalassemic patients.208
MEDICATION ERRORS AMONG PEDIATRIC HEMATOPOIETIC STEM CELL
TRANSPLANT RECIPIENTS IN AN OUTPATIENT CLINIC
McDonald, L.R., Luke, J., Jude, V., Madden, R., Chan, K. Texas Trans-
plant Institute, Methodist Children’s Hospital, San Antonio, TX
As care of hematopoietic stem cell transplant (HSCT) patients is
increasingly provided in the ambulatory setting a significant amount
of responsibility is also switched to family members. The goal of this
project was to identify the incidence and source of medication errors
in a complex outpatient population and to develop system changes to
increase safety and reliability of home administration of medications.
Between 05/11 and 08/11, a prospective study was conducted on
pediatric HSCT recipients managed in a hospital-based outpatient
clinic. Patients within one year post-transplant or later if still on im-
munosuppressive therapy were included. Medication reconciliation
was performed by a clinic nurse every visit and verified by one of
two advanced nurse practitioners (ANP). The latter compared the
information with dictated clinic notes to confirm accuracy of medi-
cation administration. For variance the ANP determined the source
of error and clinical consequence, if any. The results were conferred
with the transplant physician for change of management.
Medications were classified as immunosuppressives (IS), anti-
infectives (AI) and others (OT). 300 visits (285 allogeneic HSCT-
and 15 autologous HSCT) occurred among 49 patients during the
4-month period. 19 medication errors were identified (6% inci-
dence) among 10 patients. 5 patients experienced multiple episodes
of error. All were administration errors. 18 errors (95%) occurred
at home and one (5%) in the clinic. 18 errors were found in alloge-
neic patients, 1 in an autologous patient. 7 errors (37%) involved
IS, 7 (37%) involved AI, and 5 (26%) fromOT.Themedian time be-
fore an error was detected was 2 (range 1-24) days. Themedian num-
ber of drugs taken by each patient was 6 (range 3-14). The nature of
the errors was wrong dose (too high 42%, too low 21%) and omis-
sion of a dose (7%). The source of the error was traced to miscom-
munication in 16 events (verbal 16%, written 68%), prescriber error
once (5%), and failure of caregiver to refill medication twice (11%).
No patient demonstrated significant clinical side-effects from medi-
cation errors. Many medications given post HSCT have a narrow
therapeutic window. Family members must take responsibility for
many skills quickly post HSCT. Standardized dosing strategies
and improved communication between the caregivers and healthcare
providers may decrease error rate and improve medication adher-
ence and safety of the care delivered.209
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Children treated with hematopoietic stem cell transplantation
(HSCT) are at particular risk to develop disturbances in dental
Poster Session I S281and craniofacial development. Busulfan (Bu) is an alkylating agent
that can be combined with cyclophosphamide (Cy) in order to
avoid use of TBI in children. The hypothesis to be tested in this
study was that children conditioned with Bu/Cy have fewer distur-
bances in dental development compared to those conditioned with
TBI/Cy.
Patients andMethods:The present study included 81 recipients of
allogeneic HSCT and grafted between January 1980 and 2001. 57
children were treated with TBI and 24 with Bu/Cy. Panoramic ra-
diographs were examined for aplasia, microdontia (reduction in
crown size) and disturbances in root development of permanent
teeth.
Results: When excluding third molars 19% (11/57) in the TBI/
CY-group and 19% (5/28) in the BU/CY-group exhibited one or
more missing teeth (p 5 0.7863). In both groups there were a sta-
tistically significant negative correlation between age at HSCT and
the number of missing teeth (p\0.001). In the TBI/Cy group 23%
(13/57) compared to 52% (12/23) in the Bu/Cy group exhibited
microdontia (p 5 0.0119). Seventy-three percent (41/56) in the
TBI/CY-group compared to 87% (20/23) in the BU/CY-group ex-
hibited disturbances in root development. The mean number of
teeth exhibiting disturbances in root development was 12.2 6 9.6
in the TBI/CY-group and 10.3 6 8.6 in the BU/CY-group
(p 5 0.5726).
Conclusion: The results show that busulfan is as toxic as TBI with
regard to causing disturbances in dental development. Long-term
survivors need careful dental follow-up to facilitate early diagnosis
and planning of dental treatment.210
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Background: The onset of cutaneous complications following he-
matopoietic stem cell transplantation (HSCT) has an impact on the
well-being of post-transplant patients. These sequelae include ad-
verse drug reactions, toxic erythema of chemotherapy, viral exan-
thema, eruption of lymphocyte recovery and graft-versus-host
disease (GVHD). Such skin toxicities can have a profound effect
on quality of life (QoL). Using a dermatology-specific question-
naire, we investigated the impact of dermatologic events after
HSCT.
Methods: Patients completed the Skindex-16, a questionnaire
that measures the effects of skin disease on patient QoL with re-
spect to symptoms, emotions, and functional status, based on
a 0-6 scale from least to most severe. Correlation of Skindex-
16 scores was made to patient gender, age, ethnicity, underlying
disease, type of HSCT, conditioning regimen, post-HSCT im-
munosuppressive medications, and presence/severity of acute
and chronic GVHD according to Glucksberg criteria and
the 2005 National Institute of Health Consensus Conference
respectively.
Results:There was a statistically significant increase in mean scores
for patient emotions (49.7) related to skin toxicities followingHSCT
as compared to both symptom scores (34.5, p5 .044) and functional
status scores (19.8, p\.001). There were no significant differences
between QoL scores associated with patient gender, age, ethnicity,
underlying disease, type of HSCT, conditioning regimen, post-
HSCT immunosuppressive medications, and presence/severity of
acute and chronic GVHD.
Conclusions: GVHD and other cutaneous sequelae of HSCT
adversely impacted patient QoL with respect to emotional state
as compared to symptoms or functional derangements related to
skin eruptions post-HSCT. These results suggest that patient
counseling is an essential component of medical care for pa-
tients with GVHD and other skin toxicities that result from
transplantation.211
HEMATOPOEITIC CELL TRANSPLANT (HCT) SURVIVORSHIP: HOW MUCH
VARIANCE IN DEPRESSIVE SYMPTOMS CAN BE ACCOUNTED FOR BY
BIOMEDICAL VARIABLES?
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HCT recipients are at high risk for psychological distress, partic-
ularly depression and anxiety, with reported prevalence rates as
high as 40%, but there is a paucity of research evaluating how med-
ical treatment-related variables might contribute to these symp-
toms. Our study investigated the feasibility of a brief
psychological screening in routine outpatient care of 101 adult-
HCT survivors. Participants completed the diagnostically-focused
Patient Health Questionnaire (PHQ), assessing for depressive dis-
orders, anxiety, and substance abuse. Median time to study partic-
ipation was 276 days post-HCT (range 20-1821 days). Of the entire
cohort (18 autologous, 83 allogeneic HCT), 22% endorsed the 9-
item depressive symptoms subscale (PHQ9; range 0-27) in the clin-
ically significant range of at least moderate depression (score $ 10);
19.8% scored in the mild range (score 5-9). As mean PHQ9 scores
of autologous and allogeneic HCT did not differ significantly, we
limited further analysis to allogeneic HCT recipients only. Linear
multiple regression analysis with forced entry yielded a model ac-
counting for 22.5% of the variance in depressive symptoms
(F (8,74) 5 3.98; p\ .001).
Table. Linear Multiple Regression Model with Forced Entry
Predicting Depressive Symptoms in Allogeneic Transplant
Patients, Controlling for Relapse, Steroid Dose at Time of
Study, and Age at HCT
PREDICTORS BETA p VALUEFull Intensity* 0.32 0.004
Steroids for aGVHD prior to study** 0.42 0.001
Unrelated donor HCT*** -0.34 0.002
Any GVHD prior to study**** -0.32 0.009
Days from HCT prior to study 0.27 0.014
Relapse prior to study 0.03 0.743
Steroid dose (mg/kg) at study entry 0.17 0.100
Age at HCT 0.15 0.175*Full vs reduced intensity conditioning regimen; thus full intensity had
more depression
**Steroids for acute GVHD; thus treated with steroids were more
depressed
***Unrelated vs related; thus related had more depression
****Any GVHD (acute or chronic) before study; thus those without
GVHD had more depression
More depressive symptoms were significantly associated with full
intensity conditioning regimen, steroid treatment for acute
GVHD, and more days since transplant. Less depression was asso-
ciated with unrelated HCT compared to related HCT, and any
form of GVHD compared to none. Thus, long-term HCT survi-
vors were more likely to be depressed, and patients with GVHD
were less depressed. However, patients with acute GVHD treated
with steroids were more likely to be depressed. One explanation
may be that unrelated graft recipients and those experiencing
GVHD had lower expectations of good outcome, or greater social
support. To explore how heavily the medical predictors loaded on
somatic symptoms associated with depression, we assessed the 5
PHQ cognitive/affective items (i.e., omitting the 4 somatic items)
onto the same set of predictor variables, producing a statistically
significant model accounting for 19.4% of the variance (p\ .01),
suggesting that medical variables contributed significantly to the
variance in cognitive and affective depressive symptoms alone.
These data for this hypothesis-generating pilot are now being
used to design a future prospective study mapping the trajectory
of depression from pre-HCT through various time points post-
HCT in relation to biomedical variables.
